세계의 약물유전체학 시장 : 시장 규모 - 제공별, 기술별, 용도별, 질환 영역별, 최종 사용자별 예측(2024-2032년)

Global Pharmacogenomics Market size is anticipated to record over 10.5% CAGR from 2024 to 2032, due to increasing number of product launches, technological advancements, and efforts to reduce healthcare costs. These factors are driving the amalgamation of genetic information into drug development and personalized medicine.

Pharmacogenomics are also used for enhancing the precision of treatments and improving patient outcomes by leveraging new technologies for delivering effective care and providing valuable insights for more targeted therapies. For instance, in December 2022, MapmyGenome launched MedicaMap, an affordable pharmacogenomics solution covering over 165 drugs to enhance personalized medicine for providing insights into how individuals respond to various medications.

The market is segregated into offering, technology, application, disease area, end-user, and region.

In terms of offering, the service segment in the pharmacogenomics industry is predicted to experience significant growth rate through 2032. Pharmacogenomics are transforming the way medications are prescribed by analyzing how genetic makeups of individuals are affecting their responses to drugs. Healthcare providers are also currently identifying the most effective treatments for patients based on their unique genetic profiles by using this service.

By application, the pharmacogenomics market from the clinical research segment is expected to rise from 2024 to 2032, fueled by increasing adoption to tailor drug therapies to individual genetic profiles. Researchers are studying how genetic variations impact drug metabolism and efficacy for enhancing the personalized medicine approaches. With advancements in genetic testing and data analysis, the improvements in precision of drug therapies is leading to the development of more targeted and effective treatment plans.

Regionally, the Asia Pacific pharmacogenomics industry size is expected to grow between 2024 and 2032, propelled by the rising incidence of chronic diseases along with increasing awareness and adoption of personalized medicine. Researchers and healthcare providers are integrating pharmacogenomics into treatment plans to better address the needs of patients with chronic conditions, such as diabetes and heart disease, adding to the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing research and development investments
    • 3.2.1.2 Increasing prevalence of cancer
    • 3.2.1.3 Increasing adoption of precision medicine approaches
    • 3.2.1.4 Rising burden of adverse drug reactions
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Cost and reimbursement challenges
    • 3.2.2.2 Complexity and interpretation of genetic data
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Offering, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Kits & reagents
  • 5.2.1 Sequencing kits & reagents
  • 5.2.2 PCR kits & reagents
  • 5.2.3 Microarray kits & reagents
  • 5.2.4 Other kits & reagents
• 5.3 Service

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Sequencing
• 6.3 PCR
• 6.4 Microarray
• 6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Personalized medicine
• 7.3 Clinical research
• 7.4 Drug discovery and preclinical development

Chapter 8 Market Estimates and Forecast, By Disease Area, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Cardiovascular disorders
• 8.4 Neurological diseases
• 8.5 Infectious diseases
• 8.6 Mental health
• 8.7 Other disease areas

Chapter 9 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals & clinics
• 9.3 Academic & research institutes
• 9.4 Pharmaceutical & biotechnology companies
• 9.5 CROs

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Agilent Technologies Inc.
• 11.2 Becton, Dickinson and Company
• 11.3 Bio-Rad Laboratories Inc.
• 11.4 Charles River Laboratories
• 11.5 Danaher Corporation
• 11.6 Eurofins Scientific
• 11.7 F. Hoffmann-La Roche Ltd
• 11.8 Illumina Inc.
• 11.9 Laboratory Corporation of America Holdings
• 11.10 Mesa Labs, Inc.
• 11.11 Novogene Co., Ltd.
• 11.12 Revvity
• 11.13 Qiagen N.V.
• 11.14 Takara Bio Inc.
• 11.15 Thermo Fisher Scientific Inc.